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sion of other severe HST-related complications. Primary end-
points were response to treatment after 14 and 28 days. Secondary
endpoints were side effects and incidence of infectious complica-
tions. Treatment consisted of Campath 1H 10mg given s.c. on days
1-5. Median age was 33 years old (range:1-59) years, a ﬂudarabine-
based reduce intensive conditioning (RIC) regimen was used and
the hematopoietic cells were obtained from HLA-identical siblings
in 12 cases and one patient received stem cell from umbilical cord
blood. All but one received CSA and MTX for GvHD prophylaxis.
GvHD was classiﬁed as grade II in 5 patients, III in 6 and IV in 2;
predominant organ affected was gut in 6 cases, skin in 7, liver in 4
and combination of gut and skin in 4 patients. In 6 of the 13
patients the clinical manifestations of GVHD were noticed after
the ﬁrst 100 days of HSCT. Complete resolution of GvHD, partial
response and no response were seen respectively in 23%, 62% and
15%. Six over the 13 patients were able to decrease steroid use.
Five patients developed CMV (pp65) reactivation and 3 of them
were successfully treated with valganciclovir. All patients main-
tained complete chimerism during and after alemtuzumab therapy,
and after a median follow-up of 5 months (range, 1- 18months), 8
remain alive, 3 without evidence of GVHD. Five patients died, 3
due to GvHD and the others due to infectious complications. This
preliminary study suggests that alemtuzumab is a well-tolerated
agent and has a beneﬁcial effect in the treatment of refractory
GvHD. It is only a pilot study and more studies are needed, but we
suggest that this modality could be used early in the management
of these patients in order to improve quality of life and reduce the
long-term side effects of corticosteroids.
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GRAFT VERSUS HOST DISEASE AFTER STEM CELL ALLOTRANSPLANTA-
TION WITH LOW DOSE TBI, FLUDARABINE AND ATG
Grosskreutz, C.L.1, Scigliano, E.1, Osman, K.1, Isola, L.M.1 1Mount
Sinai Medical Center, New York, NY.
We previously showed that antithymocyte globuline (ATG)
given with TBI 200 cGy and ﬂudarabine results in high rate of
donor engraftment. Its inﬂuence on acute and chronic graft versus
host disease (GVHD) and on graft versus tumor effect is less
known. The reported rates of acute, grade II-IV GVHD after
non-myeloablative stem cell transplantation (NST) have ranged
from 20% to 58%. In the setting of NST, advanced recipient
and/or donor ages increase the risk of GVHD. In addition, treat-
ment of GVHD with high doses of corticosteroids is poorly tol-
erated in older adults. For these reasons, strategies to decrease the
incidence and severity of GVHD in NST are needed. Sixty-ﬁve
patients underwent non myeloablative stem cell transplant using
ATG horse derived 15mg/kg/day x 4 days or rabbit derived 1.5
mg/kg/day x 4 doses on days -4 to -1, TBI 200 cGy in a single
fraction given on day -5 and ﬂudarabine 30mg/m2/day x 3 doses on
days -4 to -2. Mycophenolate mofetil (MMF) 15mg/kg twice daily
and cyclosporine (CSA) 6 mg/kg twice daily were started on day -5
for GVHD prophylaxis. Patients characteristics is summarized in
Table 1. Between 30 to 60 days post transplant peak donor chi-
merism 80% was documented in 54 patients (93%) and 50-80%
donor chimerism in 4 pts (7%). At a median follow up of 862 days,
24 patients (37%) developed GVHD. The median age of the
patients with and without GVHD was 56 years respectively. Acute
GVHD (aGVHD) grade II-IV developed in 19 pts (29%). Fatal
GVHD of liver and/or gut occurred in nine pts (14%). Forty one
patients survived more than 100 days. Five patients (12%) had
chronic GVHD (cGVHD), two had extensive and three limited
involvement. Relapsed disease was observed in 22 patients (34%).
Relapsed disease was the main cause of death in patients with AML
9/13 (69%). Six patients with AML had relapsed/refractory disease
at the time of transplant. Relapse rate for patients with NHL was
29% and 33% for those with MM. Sixteen patients (25%) are alive
in CR (10 NHL and 3 MM and 3 MDS/MPD), with a median
follow up of 862 days. Infections occurred in 15 patients (23%) and
were fatal in 13 (20%). Our study conﬁrms the usefulness of ATG
in the prevention of acute and chronic graft-versus-host disease
after NST. Except for some caveats related to donor type, we were
not able to demonstrate a major impact in the rate of grade III and
IV aGVHD owing to the use of ATG. The best transplant out-
comes were seen in patients with lymphoid malignancies.
Table 1: Patients Characteristics
N 65
Age (median/range) 56 (19-71)
Male/Female 41/24
Donor
Age (median/range) 48 (20-71)
Male/Female 33/32
Matched related 42 (65%)
Matched unrelated 18 (28%)
Mismatch related 1 (1.5%)
Mismatch unrelated 4 (6%)
Female donor/Male recipient 20 (31%)
Diagnosis (%)
NHL 21 (32%)
MM 15 (23%)
AML 13 (20%)
MDS 4 (6%)
MPD 4 (6%)
ALL 2 (3%)
CLL 2 (3%)
PNH/SAA 2 (3%)
HD 1 (1.5%)
CML 1 (1.5%)
Stem cell source (%)
G-PBPC 58 (89%)
Marrow 7 (11%)
Prior ASCTx (%) 11 (17%)
Median follow up for patients alive 862 days
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ETANERCEPT AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-
HOST DISEASE
Gulbis, A.M.1, Hsu, Y.1, Neumann, J.L.1, Hymes, S.1, de Lima, M.J.1,
Hosing, C.M.1, Khouri, I.F.1, Qazilbash, M.H.1, Kebriaei, P.1,
Andersson, B.S.1, Champlin, R.E.1, Couriel, D.P.1 1University of Texas
M.D. Anderson Cancer Center, Houston, TX.
Objective: To assess the activity and toxicity of etanercept in the
salvage treatment of patients with chronic graft versus host disease
(cGVHD) failing steroids or further therapy. Patients/Methods:
Retrospective study of all patients with moderate to severe
cGVHD seen in our GVHD clinic from 11/2004 to 11/2005, who
received etanercept for the treatment of cGVHD. The diagnosis
and staging of cGVHD was based on NIH Consensus criteria. All
patients were either steroid refractory (progressive disease (PD),
stable disease (SD) or partial response (PR) despite prolonged
treatment with steroids) or steroid dependent (ﬂaring after steroid
discontinuation). Results: We identiﬁed a total of 9 patients
treated with etanercept. Organs involved included: skin (n7, 6
with sclerosis), lung (n1), eye (n3) and mouth (n1). Four
patients had involvement of cGVHD in more than 1 organ site. All
patients receive salvage with other agents in addition to steroids
prior to receiving etanercept. Seven received sirolimus, 7 received
extracorporeal photopheresis (ECP), 2 received mycophenolate
mofetil, 1 received inﬂiximab, 2 received hydroxychloroquine, and
1 received thalidomide. At initiation of etanercept, 7 patients were
on steroids, 6 patients continued ECP and 3 patients continued
multi-drug salvage regimens. Patients received etanercept 50 mg
subcutaneously (SC) weekly. Only 1 patient had a reduction in dose
to 50 mg SC every other week when response was noted. Overall
response rate was 56 % (5/9). Three of 6 patients with sclerosis had
a response, one was a complete response and 2 had a PR. The
patient with lung cGVHD had a PR and the patient cGVHD of the
mouth had a PR. Patients received between 4 to 80 doses (4
patients received greater then 20 doses) of etanercept 50 mg SC
weekly. Five of the seven patients on corticosteroids were able to
taper within one month of starting etanercept. The patient with
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lung GVHD is currently still on etanercept and stable off steroids.
Five patients are still alive currently. Three patients had SD and
one patient had PD on etanercept. Causes of death included
cGVHD (n2), disease progression (n1) and unknown cause
(n1). Conclusion: In this preliminary evaluation, etanercept was
well tolerated and had activity in patients with cGVHD of the skin,
and potentially in some cases with visceral involvement and failing
corticosteroids. Further dosing and efﬁcacy studies earlier in the
treatment of patients with cGVHD are warranted.
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ESTABLISHMENT OF A CHIMERIC NOD-Scid/IL2Rcnull TRANSPLANTA-
TION-MODEL TO EVALUATE GRAFT-VS-HOST AND GRAFT-VS-LEUKE-
MIA IMMUNE RESPONSES OF EX VIVO MODIFIED HUMAN T LYMPHO-
CYTE GRAFTS
Nonn, M.1, Khan, S.A.1, Shultz, L.D.2, Handgretinger, R.3,
Hagemann, M.1, Wehler, T.1, Meyer, R.G.1, Huber, C.1, Herr, W.1,
Hartwig, U.1 1Dept. of Medicine III, Hematology and Oncology, Jo-
hannes Gutenberg-University School of Medicine, Mainz, Germany;
2The Jackson Laboratory, Bar Harbor, ME; 3Dept. of Pedriatic Medicine
I, Hematology and Oncology, Eberhard-Karls University School of Med-
icine, Tuebingen, Germany.
Donor lymphocyte graft engineering to abrogate graft-vs-host
(GVH) reactivity while improving graft-vs-leukemia (GVL) immu-
nity is of particular interest in allogeneic hematopoietic stem cell
transplantation. We have recently described a protocol to achieve
short-term expansion of donor-derived leukemia-reactive T cells
ex vivo followed by CD137-mediated selective depletion of allo-
reactivity (SAD) to major and ubiquitously expressed minor histo-
compatibility antigens using allogeneic ﬁbroblasts1. For evaluating
GVH and GVL immune responses of modiﬁed donor T cells in
vivo we have now used NOD-scid IL2Rcnull mice to establish a
chimeric transplantation model. GVH reactivity after SAD was
examined by subcutaneously implanting skin substitutes composed
of a collagen-based matrix which contained 6105 human primary
ﬁbroblasts derived from the same pool previously used for SAD.
Upon implantation, substitutes remained viable, induced angio-
genesis and could be dissolved to cell suspensions for further
analyses when removed 3 weeks after implantation. Following
intravenous injection of 1.5107 preactivated untreated allogeneic
human CD3 T cells per mouse, 7–10% of T cells migrated into
the skin substitutes explanted 14 days post adoptive transfer. Such
an enrichment of T cells was not observed when the same number
of CD137-allodepleted T cells were injected. Since xenogenic
GVH reactivity was observed depending on the amount of T cells
used current studies investigate whether residual murine antigen-
presenting cells initiate xeno-reactivity and address its impact on
the migration of T cells into the skin substitutes. To study GVL
immunity we further transplanted different amounts of acute my-
eloid leukemia (AML) cells derived from primary AML patients
(M4 and M5 subtype) into NOD-scid IL2Rcnull mice. Eight
weeks after injection 61% and 17% of isolated spleen and bone
marrow cells, respectively, stained positive for a shared HLA-
class-I epitope and also expressed CD34 as measured by ﬂow
cytometry. Currently, studies are in progress to examine immune
responses to AML by adoptive transfer of human AML-stimulated
allodepleted T cell lines devoid of alloreactivity to AML HLA-
matched ﬁbroblasts. In summary, our NOD-scid/IL2Rcnull trans-
plantation model may be a valuable tool for evaluating GVH and
GVL immunity in vivo following modiﬁcations of donor T lym-
phocytes grafts in vitro.
1 Wehler T and Nonn M, et al. 2006. Blood;epub. Aug. 24.
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ALLOANTIGENS EXPRESSION ON HOST NON-HEMATOPOIETIC CELLS
LEADS TO DONOR T CELL EXHAUSTION AND REDUCES GVL EFFECTS
Hashimoto, D.1, Asakura, S.2, Matsuoka, K.-I.2, Sakoda, Y.2,
Koyama, M.2, Aoyama, K.2, Tanimoto, M.2, Teshima, T.1 1Center for
Cellular and Molecular Medicine, Kyushu University Hospital,
Fukuoka, Japan; 2Biopathological Science, Okayama University Grad-
uate School of Medicine and Dentistry, Okayama, Japan.
We previously showed that alloantigen expression on host
non-hematopoietic cells impaired graft-versus-leukemia (GVL)
effects after allogeneic hematopoietic stem cell transplantation
using chimeric mice expressing alloantigens on hematopoietic
cells alone. C3.Sw (H-2b) mice were lethally irradiated and
injected with T cell depleted bone marrow cells (TCD-BM)
from multiple minor histocompatibilitiy antigens (mHAs) dis-
parate B6 (H-2b) donors. These chimeric mice (BC chimeras),
expressing B6-derived mHAs only on hematopoietic cells, were
lethally irradiated and transplanted with TCD-BM and CD8 T
cells from C3.Sw donors together with B6-derived leukemia
cells, EL-4. In controls we used B63B6 chimeras (BB chime-
ras), expressing B6-derived mHAs on both hematopoietic and
non-hematopoietec cells, as recipients. BB chimeras trans-
planted with TCD-BM  CD8 T cells from C3.Sw exhibited
a signiﬁcant GVL effect but died from leukemia signiﬁcantly
earlier than BC chimeras. To further conﬁrm that alloantigen
expression on non-hematopoietic cells impairs GVL activity,
similar experiments were performed using B63B6-2m deﬁ-
cient chimeras (B- chimeras), lacking functional MHC class I
molecules on non-hematopoietic cells. Leukemia mortality was
signiﬁcantly reduced in B- chimeras compared to BB chimeras,
thus conﬁrming that alloantigen expression on host non-hema-
topoietic cells impairs GVL effects. To elucidate the mechanism
of the reduced GVL effects in BB chimeras, T cells were
isolated from lymph nodes and spleen of chimeras after BMT.
Numbers of donor CD8 T cells in lymph nodes and spleens of
BB recipients decreased much earlier than in BC chimeras in
association with an enhanced apoptosis. CTL activities against
EL-4 signiﬁcantly reduced in BB recipients compared to BC and
B- chimeras. PD-1 expressions on CD8 T cells from BB
chimeras were signiﬁcantly enhanced compared to those from
BC chimeras. These results suggest that alloantigen expression
on host non-hematopoietic cells leads to exhaustion and dys-
function of donor T cells and impairment of GVL effects.
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THE ROLE OF SNPS WITHIN RECEPTORS OF INNATE IMMUNITY IN
OUTCOME FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:
SYNERGISM BETWEEN TLR5-STOP AND NOD2/CARD15?
Holler, E.1, Krueger, B.2, Rogler, G.3, Brenmoehl, J.1,
Dickinson, A.M.4, Greinix, H.5, Wolff, D.6, Finke, J.7, Hahn, J.1,
Kraemer, B.2, Andreesen, R.1 1Division of Haematology/Oncology, Uni-
versity Medical Centre, Regensburg, Germany; 2Department of Internal
Medicine II, University Medical Centre, Regensburg, Germany; 3De-
partment of Internal Medicine I, University Medical Centre, Regens-
burg, Germany; 4School of Clinical and Laboratory Sciences, University
of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 5De-
partment of Internal Medicine, University of Vienna, Vienna, Austria;
6Department of Haematology and Oncology, University of Rostock, Ros-
tock, Germany; 7Department of Haematology and Oncology, University
Medical Centre, Freiburg, Germany.
Our group recently reported an association of single nucleo-
tide polymorphisms (SNPs) within NOD2/CARD15, an impor-
tant intracytoplasmatic receptor of the bacterial ligand mu-
ramyl-dipeptide, with severe GvHD, treatment related
mortality (TRM) and outcome following allogeneic stem cell
transplantation (SCT). As these studies suggested a major role
of dysregulated epithelial inﬂammation, we now tested the role
of SNPs within further receptors involved in cellular sensing of
bacterial ligands. SNPs reported for TLR2, TLR3, TLR4, TLR5
and TLR9 were assessed in recipient (R) and donor (D) DNA
from 259 HLA-identical sibling and 294 matched unrelated
donor transplants. Acute GvHD grade III/IV, 1-yr- and overall
TRM as well as overall survival were correlated with results of
SNP typing, and the inﬂuence of major clinical risk factors as
well as previously assessed presence or absence of NOD2/
CARD15 SNPs was investigated with univariate and multivariate
analyses.
Whereas major SNPs within TLR2, 3, 4 and 9 failed to show
clear associations, the presence of a TLR5-stop codon in the
recipient (n58) showed a trend for higher severe GvHD (22%
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